Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide

Mervyn Singer(Bury College), Lucie H. Clapp(The London College), Flaminia Coluzzi(Sapienza University of Rome), Alastair O’Brien(The Royal Free Hospital)
The Lancet
May 1, 2005
10.1016/s0140-6736(05)66619-6
Cited by 38

Related Papers

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017
|JAMA|2020|1k
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
Clinical review: Update on hemodynamic monitoring - a consensus of 16
|Critical Care|2011|415
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390